Status:
COMPLETED
A Novel Formulation of Sildenafil-loaded Nanocarriers for Treatment of Alopecia Areata
Lead Sponsor:
Assiut University
Conditions:
Alopecia Areata
Eligibility:
All Genders
10-40 years
Phase:
EARLY_PHASE1
Brief Summary
Alopecia areata (AA) is a common cause of nonscarring alopecia that occurs in a patchy, confluent, or diffuse pattern. Many theories were implicated in pathogenesis of AA, such as an autoimmune lympho...
Detailed Description
The aim of the present work was to optimize sildenafil-loaded liposomes which could enhance percutaneous absorption and follicular penetration of sildenafil achieving improved therapeutic efficiency w...
Eligibility Criteria
Inclusion
- • Patients with a clinical and dermoscopic diagnosis of patchy alopecia areata of the scalp.
Exclusion
- Alopecia totalis/universalis.
- Ophiasis.
- Those with systemic and/or other dermatological diseases.
- Those receiving treatment for a lopecia areata in the previous 3 months.
Key Trial Info
Start Date :
July 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT06527729
Start Date
July 1 2021
End Date
October 1 2022
Last Update
July 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Assiut university
Asyut, Egypt